Business Wire

Bloom Announces Early 2026 UK Launch, Expanding into Europe with New Garden Pharma as Exclusive Manufacturer

Share

The Bloom Brand, a recognized U.S. leader in cannabis vape, is making its international debut in the United Kingdom through an exclusive partnership with New Garden Pharma, a leading European EU-GMP cannabis operator. Together, the two companies will launch Bloom’s award-winning Classic and Live vape collections in the UK in Q1 2026.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623573625/en/

This marks Bloom’s first international market expansion, as the company continues its global growth strategy with additional EU markets in development for 2026 and beyond. UK patients will gain access to Bloom’s superior formulations and proprietary hardware systems.

For more than a decade, Bloom has built its reputation on delivering terpene-rich, flavor-forward strains paired with reliable technology. The brand has an established and leading presence across leading U.S. markets including California, Illinois, Florida, Michigan, Missouri, New Jersey, New Mexico, New York, and Virginia.

“Expanding into the UK is a pivotal step towards our mission to reshape the global cannabis experience,” said Ovidiu (David) Chiorpec, Director of Business Development at Bloom. “We’ve spent over a decade building a brand that patients trust in the U.S., and we’re excited to introduce the UK consumer to a new level of excellence and sophistication in the vape category.”

New Garden Pharma, medical subsidiary of New Garden Group, is a trusted name in European cannabis manufacturing who combines a unique supply chain model with a proven track record in regulatory compliance and market expansion. With established infrastructure across the continent, the company will lead Bloom’s UK entry — ensuring a compliant, efficient, and scalable launch across all channels.

“We’re excited to welcome Bloom to the UK market,” said Alexey Brylev, CEO of New Garden Group. “As an established operator across European medical cannabis markets, we bring the EU-GMP manufacturing expertise, local insight, and regulatory know-how needed to help global brands thrive. This partnership reflects our broader mission: to deliver world-class products to European patients and to raise the bar for quality, safety, and innovation across the continent.”

For more information, visit thebloombrand.com or Instagram (@bloomforthepeople) and newgardenpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250623573625/en/

Contacts

Media Contact:
Allison Pankow – CMO Bloom | allison@thebloombrand.com

New Garden Pharma Contact:
Delia Flanagan – Business Development Manager|
delia.flanagan@newgardenpharma.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NuORDER by Lightspeed Expands Luxury Retail Footprint with Saks Global24.6.2025 13:02:00 EEST | Press release

NuORDER by Lightspeed, a leading global commerce platform that enables retailers and brands to connect, collaborate, and make smarter buying decisions, has established an expanded partnership with Saks Global. Saks Fifth Avenue has leveraged NuORDER to make informed buying decisions and enhance efficiency. Now, NuORDER’s capabilities will be extended to Neiman Marcus and Bergdorf Goodman to help Saks Global further its efforts to reinvent the luxury shopping experience. “With the continuous evolution of luxury consumer shopping preferences, we’re committed to building a luxury fashion assortment that is both relevant and inspiring for our customers,” said Paolo Riva, Chief Brand Partnerships & Buying Officer, Saks Fifth Avenue and Neiman Marcus. “We’re pleased to partner with NuORDER in our efforts to drive timely buying decisions in collaboration with our brand partners, enabling us to meet our customers with a refined edit of the latest fashion through highly personalized shopping ex

Cirium Introduces First AI-Powered Solution for On-Time Performance Analysis24.6.2025 12:00:00 EEST | Press release

Cirium, the global leader in aviation analytics, has launched OTP Improvement AI, a groundbreaking generative AI-powered solution designed to transform how airlines and airports analyze and enhance their On-Time Performance (OTP). This innovative tool addresses long-standing challenges in operational efficiency and disruption management, offering faster, smarter, and more proactive decision-making capabilities. OTP Improvement AI sets itself apart by addressing the specific challenges airlines and airports face, such as the time-intensive nature of traditional OTP analysis and the struggle to manage cascading delays caused by factors like weather or technical issues. By using advanced generative AI, the platform transforms complex data into precise insights, enabling operators to trends, streamline resources, and make swift decisions that minimize delays and improve the overall passenger experience. “Operational disruptions, whether caused by weather, strikes, or unforeseen technical i

Zambon Announces Approval and Launch in China of the Intravenous Formulation of Fluimucil® (N-acetylcysteine)24.6.2025 11:00:00 EEST | Press release

Zambon, a multinational chemical-pharmaceutical company founded on the history and values of an Italian family and committed to innovate cure and care to make patients’ lives better, announces the approval by Chinese regulatory authorities and the launch on the Chinese market of the intravenous (IV) formulation of Fluimucil® (N-acetylcysteine). This milestone marks a significant step in the company’s commitment to global therapeutic innovation in respiratory diseases, reflecting its dedicated focus on both clinical research and patient care. Already available in several international markets, Fluimucil® IV represents a new option for Chinese patients, where it can provide an important hospital-based therapeutic option for treating respiratory diseases characterized by excessive mucus secretion. The approval in China follows a locally conducted clinical development program, a Phase 1 and a Phase 3 clinical trial that confirmed the drug’s safety, tolerability, and efficacy profile. The P

Imperva Application Security Integrates API Detection and Response, Setting A New Standard in API Security24.6.2025 10:00:00 EEST | Press release

Thales today announced new detection and response capabilities in the Imperva Application Security platform to protect against business logic attacks, such as Broken Object Level Authorization (BOLA) – the leading threat in the OWASP API Security Top 10. By integrating real-time detection with automated mitigation of risky APIs, BOLA attacks, unauthenticated APIs, and deprecated APIs, Imperva Application Security platform delivers comprehensive protection against unauthorized data exposure and other complex business logic vulnerabilities across cloud and on-premises environments. APIs have become the backbone of modern applications, enabling businesses to seamlessly connect services, optimize operations, and deliver personalized experiences at scale. According to Imperva Threat Research, APIs accounted for 71% of all web traffic. More recently, the team observed a sharp rise in API-directed attacks, with 44% of advanced bot traffic targeting APIs, compared to just 10% targeting web app

SWARM Biotactics Raised €13M to Advance Bio-Robotics From Lab to Field24.6.2025 09:43:00 EEST | Press release

SWARM Biotactics, developer of bio-robotic systems based on fully controllable living insects for mission-critical operations, has secured €10 million in seed funding, bringing its total raised to €13 million, including a €3 million pre-seed. The round was backed by a consortium of international investors from Europe, the United States, and Australia, including Vertex Ventures US, Possible Ventures, and Capnamic, who was the first investor in the pre-seed round. Several early backers also increased their stakes in the oversubscribed round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623790761/en/ A SWARM Biotactics bio-robotic unit equipped with a custom sensor backpack for intelligence gathering in inaccessible terrain. (Photo: SWARM Biotactics) UNMATCHED ACCESS FOR CRITICAL MISSIONS SWARM Biotactics is creating a new category of robotics: living, intelligent systems designed for environments where machines can’t go—c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye